HomeCompareABC vs ARCC

ABC vs ARCC: Dividend Comparison 2026

ABC yields 1.08% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABC wins by $6.3K in total portfolio value· pulled ahead in Year 7
10 years
ABC
ABC
● Live price
1.08%
Share price
$179.98
Annual div
$1.94
5Y div CAGR
34.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.8K
Annual income
$2,940.21
Full ABC calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — ABC vs ARCC

📍 ABC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABCARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABC + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABC pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABC
Annual income on $10K today (after 15% tax)
$91.62/yr
After 10yr DRIP, annual income (after tax)
$2,499.18/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, ABC beats the other by $2,498.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABC + ARCC for your $10,000?

ABC: 50%ARCC: 50%
100% ARCC50/50100% ABC
Portfolio after 10yr
$27.7K
Annual income
$1,470.68/yr
Blended yield
5.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

ABC
Analyst Ratings
20
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$171.00
-5.0% upside vs current
Range: $150.00 — $190.00
Altman Z
4.6
Piotroski
6/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABC buys
3
ARCC buys
0
PoliticianChamberTickerTypeAmountDate
Tommy Tuberville🏛 Senate$ABC▼ Sell$15,001 - $50,0002022-01-21
Tommy Tuberville🏛 Senate$ABC▼ Sell$15,001 - $50,0002022-01-21
Michael McCaul🏢 House$ABC▲ Buy$50,001 - $100,0002021-03-01
Michael McCaul🏢 House$ABC▲ Buy$50,001 - $100,0002021-03-01
Gilbert Cisneros🏢 House$ABC▼ Sell$1,001 - $15,0002019-05-09
Pete Sessions🏢 House$ABC▼ Sell$15,001 - $50,0002017-11-27
Thomas Suozzi🏢 House$ABC▼ Sell$15,001 - $50,0002017-01-05
Pete Sessions🏢 House$ABC▲ Buy$15,001 - $50,0002015-07-31
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABCARCC
Forward yield1.08%10.82%
Annual dividend / share$1.94$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR34.4%-50%
Portfolio after 10y$30.8K$24.5K
Annual income after 10y$2,940.21$1.16
Total dividends collected$9.6K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy
Analyst price target$171.00$21.88

Year-by-year: ABC vs ARCC ($10,000, DRIP)

YearABC PortfolioABC Income/yrARCC PortfolioARCC Income/yrGap
1$10,845$144.87$11,381$541.15$536.00ARCC
2$11,801$197.34$12,621$284.08$820.00ARCC
3$12,897$269.74$13,827$145.31$930.00ARCC
4$14,170$370.27$15,062$73.43$892.00ARCC
5$15,673$510.99$16,364$36.89$691.00ARCC
6$17,480$709.92$17,757$18.49$277.00ARCC
7← crossover$19,698$994.53$19,258$9.25+$440.00ABC
8$22,485$1,407.72$20,880$4.63+$1.6KABC
9$26,077$2,018.33$22,636$2.32+$3.4KABC
10$30,843$2,940.21$24,539$1.16+$6.3KABC

ABC vs ARCC: Complete Analysis 2026

ABCStock

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Full ABC Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this ABC vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABC vs SCHDABC vs JEPIABC vs OABC vs KOABC vs MAINABC vs HTGCABC vs GBDCABC vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.